DK0549660T3 - Forøgelse af glutathionniveauer med glutamin - Google Patents

Forøgelse af glutathionniveauer med glutamin

Info

Publication number
DK0549660T3
DK0549660T3 DK91916683T DK91916683T DK0549660T3 DK 0549660 T3 DK0549660 T3 DK 0549660T3 DK 91916683 T DK91916683 T DK 91916683T DK 91916683 T DK91916683 T DK 91916683T DK 0549660 T3 DK0549660 T3 DK 0549660T3
Authority
DK
Denmark
Prior art keywords
glutamine
mammal
tissue
equivalent
increase
Prior art date
Application number
DK91916683T
Other languages
English (en)
Inventor
Douglas W Wilmore
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of DK0549660T3 publication Critical patent/DK0549660T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Seasonings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK91916683T 1990-09-20 1991-09-11 Forøgelse af glutathionniveauer med glutamin DK0549660T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/585,846 US5248697A (en) 1990-09-20 1990-09-20 Enhancement of glutathione levels with glutamine
PCT/US1991/006575 WO1992004895A1 (en) 1990-09-20 1991-09-11 Enhancement of glutathione levels with glutamine

Publications (1)

Publication Number Publication Date
DK0549660T3 true DK0549660T3 (da) 1999-12-13

Family

ID=24343212

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91916683T DK0549660T3 (da) 1990-09-20 1991-09-11 Forøgelse af glutathionniveauer med glutamin

Country Status (11)

Country Link
US (1) US5248697A (da)
EP (1) EP0549660B1 (da)
JP (1) JP3546227B2 (da)
AT (1) ATE181236T1 (da)
AU (1) AU651624B2 (da)
CA (1) CA2091766C (da)
DE (1) DE69131352T2 (da)
DK (1) DK0549660T3 (da)
ES (1) ES2133289T3 (da)
GR (1) GR3031129T3 (da)
WO (1) WO1992004895A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5040493A (en) * 1992-11-30 1994-06-09 Transcend Therapeutics, Inc Method for treating systemic inflammatory response syndrome
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
US5438075A (en) 1993-03-30 1995-08-01 Skubitz; Keith M. Oral glutamine to reduce stomatitis
EP0656201A1 (en) * 1993-11-09 1995-06-07 Transcend Therapeutics, Inc. Use of stimulators of glutathione synthesis as hait growth promotors
US6001878A (en) * 1994-01-11 1999-12-14 Van Leeuwen; Paulus Aloisius Marie Method of treating disorders of the animal or human body by administering amino acids
US6251857B1 (en) 1995-12-14 2001-06-26 Novelos Therapeutics, Inc. Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof
RU2089179C1 (ru) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20030099722A1 (en) * 2001-10-09 2003-05-29 Baxter Jeffrey H. Methods and compositions for providing glutamine
MXPA05001267A (es) * 2002-08-01 2005-10-18 Aesgen Inc Tratamiento mejorado de cancer con glutamina.
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
WO2005012904A1 (en) * 2003-08-01 2005-02-10 Aesgen, Inc. Compositions and methods for monitoring breast cancer treatment
AU2006279218B2 (en) 2005-08-11 2013-05-02 Adetherapeutics, Inc. Reducing post-operative adhesion formation with intraperitoneal glutamine
EP2077110A4 (en) * 2006-09-29 2012-06-27 Ajinomoto Kk GLUTAMINE-CONTAINING COMPOSITION FOR INCREASING BLOOD FLOW
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine
WO2008123298A1 (ja) * 2007-03-26 2008-10-16 Hirofumi Matsui 癌患者用輸液製剤
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3164463D1 (en) * 1980-11-12 1984-08-02 Mitsubishi Chem Ind Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system

Also Published As

Publication number Publication date
WO1992004895A1 (en) 1992-04-02
US5248697A (en) 1993-09-28
CA2091766C (en) 2002-10-15
ATE181236T1 (de) 1999-07-15
DE69131352D1 (de) 1999-07-22
JPH06501000A (ja) 1994-01-27
CA2091766A1 (en) 1992-03-21
EP0549660A1 (en) 1993-07-07
GR3031129T3 (en) 1999-12-31
AU651624B2 (en) 1994-07-28
EP0549660B1 (en) 1999-06-16
DE69131352T2 (de) 1999-11-18
JP3546227B2 (ja) 2004-07-21
EP0549660A4 (en) 1993-10-13
ES2133289T3 (es) 1999-09-16
AU8549491A (en) 1992-04-15

Similar Documents

Publication Publication Date Title
DK0549660T3 (da) Forøgelse af glutathionniveauer med glutamin
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
MX9204381A (es) Metodo para tratar inflamacion ocular
TR200402565T4 (tr) Hepatit delta virüsü enfeksiyonunun tedavi edilmesinde ß-L-2'-deoksi-nükleosidlerin kullanımı
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DE69130529T2 (de) Behandlung von erektionversagen
WO2004002999A3 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
DK0933995T3 (da) Fremgangsmåde til behandling af endotelskader
DK0664708T3 (da) Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
DE69719931T2 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
DK1014990T3 (da) Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
EA199900431A1 (ru) Способ профилактики рака молочной железы
DK0983072T4 (da) Fruktanholdige sammensætninger til forebyggelse og behandling af coloncancer
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
EP0369216A3 (en) Pharmaceutical preparation based on ester derivatives of hecogenine, and their use in treating benign prostatic hyperplasia
DK0458590T3 (da) Behandling af okulær hypertension med en synergistisk konbination
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
DK178188A (da) Antivirusmiddel
DK0430551T3 (da) Behandling af hjertedysfunktion med 15-keto-prostaglandinforbindelser
DK0458587T3 (da) Behandling af okulær hypertension med en synergistisk kombination til ophthalmisk anvendelse
ATE133337T1 (de) Behandlung des glaukoms mit synergistischer kombination
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis